Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
Mutations on NHR (N-terminal heptad repeat) associated with resistance to fusion inhibitor were observed. In addition, mutations on CHR (C-terminal heptad repeat) accompanied NHR mutations of gp41 are noted in many cases, like N43D/S138A double mutation. In this work, we explored the drug resistant mechanism of N43D mutation and the role of S138A second mutation in drug resistance. The binding modes of the wild type gp41 and the two mutants, N43D and N43D/S138A, with the HIV-1 fusion inhibitor C34, a 34-residue peptide mimicking CHR of gp41, were carried out by using molecular dynamics simulations. Based on the MD simulations, N43D mutation affects not only the stability of C34 binding, but also the binding energy of the inhibitor C34. Because N43D mutation may also affect the stable conformation of 6-HB, we introduced S138A second mutation into CHR of gp41 and determined the impact of this mutation. Through the comparative analysis of MD results of the N43D mutant and the N43D/S138A mutant, we found that CHR with S138A mutation shown more favorable affinity to NHR. Compelling differences in structures have been observed for these two mutants, particularly in the binding modes and in the hydrophobic interactions of the CHR (C34) located near the hydrophobic groove of the NHR. Because the conformational stability of 6-HB is important to HIV-1 infection, we suggested a hypothetical mechanism for the drug resistance: N43D single mutation not only impact the binding of inhibitor, but also affect the affinity between NHR and CHR of gp41, thus may reduce the rate of membrane fusion; compensatory mutation S138A would induce greater hydrophobic interactions between NHR and CHR, and render the CHR more compatible to NHR than inhibitors.
College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China.
Xueting
X
Ma
College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China.
Jianjun
J
Tan
College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China.
Min
M
Su
College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China.
Chunhua
C
Li
College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China.
Xiaoyi
X
Zhang
College of Life Science and Bioengineering, Beijing University of Technology, Beijing, China.
Cunxin
C
Wang
D024882:Drug Resistance, Viral / Q000235:genetics; D015700:HIV Envelope Protein gp41 / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D023581:HIV Fusion Inhibitors / Q000737:chemistry*; D056004:Molecular Dynamics Simulation; D020125:Mutation, Missense; D010446:Peptide Fragments / Q000737:chemistry*; D017434:Protein Structure, Tertiary
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; C514787:gp41 protein, Human immunodeficiency virus 1; C407149:peptide C34